Multicenter trial of naloxone in alzheimer's disease

V. W. Henderson; E. Roberts; C. Wimer; E. L. Bardolph; H. C. Chui; A. R. Damasio; P. J. Eslinger; M. F. Folstein; L. S. Schneider; E. L. Teng; L. E. Tune; L. P. Weiner; P. J. Whitehouse

doi:10.1002/ana.410250413

Multicenter trial of naloxone in alzheimer's disease

V. W. Henderson, E. Roberts, C. Wimer, E. L. Bardolph, H. C. Chui, A. R. Damasio, P. J. Eslinger, M. F. Folstein, L. S. Schneider, E. L. Teng, L. E. Tune, L. P. Weiner, P. J. Whitehouse

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

Original language	English (US)
Pages (from-to)	404-406
Number of pages	3
Journal	Annals of Neurology
Volume	25
Issue number	4
DOIs	https://doi.org/10.1002/ana.410250413
State	Published - Apr 1989

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.1002/ana.410250413

Cite this

@article{1e7230528ec3491480c2be24eca78c48,

title = "Multicenter trial of naloxone in alzheimer's disease",

abstract = "In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.",

author = "Henderson, {V. W.} and E. Roberts and C. Wimer and Bardolph, {E. L.} and Chui, {H. C.} and Damasio, {A. R.} and Eslinger, {P. J.} and Folstein, {M. F.} and Schneider, {L. S.} and Teng, {E. L.} and Tune, {L. E.} and Weiner, {L. P.} and Whitehouse, {P. J.}",

year = "1989",

month = apr,

doi = "10.1002/ana.410250413",

language = "English (US)",

volume = "25",

pages = "404--406",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Multicenter trial of naloxone in alzheimer's disease

AU - Henderson, V. W.

AU - Roberts, E.

AU - Wimer, C.

AU - Bardolph, E. L.

AU - Chui, H. C.

AU - Damasio, A. R.

AU - Eslinger, P. J.

AU - Folstein, M. F.

AU - Schneider, L. S.

AU - Teng, E. L.

AU - Tune, L. E.

AU - Weiner, L. P.

AU - Whitehouse, P. J.

PY - 1989/4

Y1 - 1989/4

N2 - In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

AB - In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0024523689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024523689&partnerID=8YFLogxK

U2 - 10.1002/ana.410250413

DO - 10.1002/ana.410250413

M3 - Article

C2 - 2653175

AN - SCOPUS:0024523689

SN - 0364-5134

VL - 25

SP - 404

EP - 406

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

Multicenter trial of naloxone in alzheimer's disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this